Economic burden of comorbidities in patients with psoriasis is substantial

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 2, 2011, Pages 157-163

  Kimball, A B ^a   Guerin A ^b   Tsaneva, M ^b   Yu, A P ^b   Wu, E Q ^b   Gupta, S R ^c   Bao, Y ^c   Mulani, P M ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ANALYSIS GROUP   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

comorbidity; economic; health care costs; psoriasis

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTPATIENT CARE; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; STATISTICAL PARAMETERS;

ADULT; COMORBIDITY; COST OF ILLNESS; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 78650966287     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03730.x     Document Type: Article

References (34)

1. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835. (Pubitemid 44556851)
2. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R,. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35.
3. Schmitt J, Ford DE,. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis-a structural equations modeling approach. Gen Hosp Psychiatry 2007; 29: 134-140.
4. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on healthcare costs and patient work loss. J Am Acad Dermatol 2008; 59: 772-780.
5. The Lewin Group, Inc. The burden of skin diseases. 2004. URL (last accessed: 8 May 2009).
6. Mrowietz U, Elder JT, Barker J,. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006; 298: 309-319.
7. Gottlieb AB, Chao C, Dann F,. Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5-21.
8. Zachariae H,. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4: 441-447.
9. Leonard DG, O'Duffy JD, Rogers RS,. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978; 53: 511-518.
10. Scarpa R, Oriente P, Pulino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984; 23: 246-250.
11. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
12. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155. (Pubitemid 351158580)
13. Wakkee M, Thio HB, Prens EP, et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1-9.
14. Friedewald V, Cather J, Gelfand J, et al. AJC Editor's Consensus: psoriasis and coronary artery disease. Am J Cardiol 2008; 102: 1631-1643.
15. Federman DG, Shelling M, Prodanovich S, et al. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 2009; 160: 1-7.
16. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
17. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123-127.
18. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-526.
19. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.
20. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE,. Heart disease in psoriasis. J Am Acad Dermatol 2007; 57: 347-354.
21. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
22. US Department of Health and Human Services. International Classification of Diseases, Ninth Revision, Clinical Modification, 4th edn. US Government Printing Office, Washington, DC, 1991.
23. Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004; 20: 1929-1936.
24. Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49: 897-899.
25. Pariser D, Bagel J, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007; 143: 239-242.
26. Charlson ME, Pompei P, Ales KL, McKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-383.
27. Stern RS,. PUVA follow-up study. Inpatient hospital care for psoriasis: a vanishing practice in the United States. J Am Acad Dermatol 2003; 49: 445-450.
28. Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008; 159: 1116-1123.
29. Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA 2003; 289: 3135-3144. (Pubitemid 37432889)
30. Grover SA, Ho V, Lavoie F, et al. The importance of indirect costs in primary cardiovascular disease prevention. Arch Intern Med 2003; 163: 333-339.
31. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008; 217: 27-37.
32. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
33. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218.
34. Revicki D, Willian MK, Mentor A, et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260-270.